✓ Translated by DotMD AI Clinical Council Source: Drug design, development and therapy • Randomized Controlled Trial

Verify Primary Source: NIH PubMed PMID #29692602 ↗

Randomized Controlled Trial: Pharmacokinetic interactions and tolerability of rosuvastatin and ezetimibe: an open-label, randomized, multiple-dose, crossover study in healthy male volunteers (N = 24)

Original Paper Title: “Pharmacokinetic interactions and tolerability of rosuvastatin and ezetimibe: an open-label, randomized, multiple-dose, crossover study in healthy male volunteers”

Elena Rostova (AI Quant) Rigor Score

82 / 100

Sample Size (Participants)

N = 24

Evidence Classification

Randomized Controlled Trial

Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways

Combined administration of rosuvastatin and ezetimibe was well tolerated. No clinically significant PK interactions between rosuvastatin and ezetimibe were observed when the 2 drugs were administered concomitantly.
Study Design & Sample: Randomized Controlled Trial published in Drug design, development and therapy (N = 24 human participants).
Biostatistical Rigor Score: 82/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Drug design, development and therapy (2018), this randomized controlled trial evaluating 24 human participants investigated: Rosuvastatin is a synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor that effectively reduces low-density lipoprotein cholesterol levels. Key clinical takeaway: Combined administration of rosuvastatin and ezetimibe was well tolerated. No clinically significant PK interactions between rosuvastatin and ezetimibe were observed when the 2 drugs were administered concomitantly.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Drug design, development and therapy, 2018-01-15; N = 24; Rigor 82/100): Combined administration of rosuvastatin and ezetimibe was well tolerated. No clinically significant PK interactions between rosuvastatin and ezetimibe were observed when the 2 drugs were administered concomitantly.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Randomized Controlled Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: rosuvastatin-calcium → Rx: rosuvastatin → Rx: ezetimibe → Rx: ezetimibe-and-simvastatin → Condition: vitamin-d → Condition: vitamin-d-deficiency →

Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 29692602: Randomized Controlled Trial: Pharmacokinetic interactions and tolerability of rosuvastatin and ezetimibe: an open-label, randomized, multiple-dose, crossover study in healthy male volunteers (N = 24)

3 of 3 Free Questions Remaining